HOWL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HO

Mkt Cap

$47.5M

Volume

300.51K

Next Earnings

November 3rd

Loading chart

HO

HOWLWerewolf Therapeutics, Inc. Common Stock

HOWL

Pay with—

Available Balance0.00

HO

Mkt Cap

$47.6M

Volume

300.51K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.Zacks Investment Research · Oct 16, 2026

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyWerewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy) rating based on upward trends in earnings estimates. The company's consensus estimate has increased 17.6% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.Zacks Investment Research · Oct 13, 2026

TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.Zacks Investment Research · Oct 13, 2026

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.Zacks Investment Research · Oct 13, 2026

New Strong Buy Stocks for October 9thZacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Lumentum Holdings (optical/photonic products), Werewolf Therapeutics (cancer biopharmaceutical), Perion Network (digital advertising), Goldman Sachs BDC (business development), and Griffon Corporation (diversified management).Zacks Investment Research · Oct 9, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).GlobeNewswire Inc. · Sep 3, 2026

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesWerewolf Therapeutics announced it is exploring strategic alternatives to maximize stockholder value, including potential sale, merger, asset sale, or licensing arrangements. The company reported improved financial metrics for 2025 with reduced R&D and G&A expenses, lower net losses compared to 2024, and cash reserves of $57.1 million expected to fund operations into Q4 2026. Piper Sandler has been engaged as exclusive financial advisor for the strategic evaluation process.GlobeNewswire Inc. · Mar 27, 2026

Deal Dispatch: Funko For Sale? Caesars Casino Weighs Offers, iPic BankruptMultiple major M&A activities and bankruptcies dominate the market: Funko surges 25% after investor urges sale exploration; Caesars Entertainment weighs takeover offers including from billionaire Tilman Fertitta; Netflix loses Warner Bros. bidding war to Paramount Skydance's $111B offer; GSK acquires 35Pharma for $950M; and iPic Theaters files for Chapter 11 bankruptcy.Benzinga · Feb 27, 2026

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingWerewolf Therapeutics will present three scientific posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting research on conditionally activated immune therapeutics for cancer treatment.GlobeNewswire Inc. · Oct 3, 2025

Werewolf Reports No Revenue in Fiscal Q2Werewolf Therapeutics reported Q2 2025 results with no revenue, continued investment in cancer immunotherapy research, and focus on advancing clinical trials for WTX-124 and WTX-330 drug candidates.The Motley Fool · Aug 14, 2025

to start trading

HO

HOWLWerewolf Therapeutics, Inc. Common Stock

HOWL

Pay with—

Available Balance0.00

Your PositionYou don't own any HOWL yet.

Related Tickers

Earnings